Chicago, ILNCT07290543Now EnrollingIRB Ready

Hematopoietic and Lymphatic System Neoplasm Clinical Trial in Chicago, IL

Access cutting-edge hematopoietic and lymphatic system neoplasm treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access hematopoietic and lymphatic system neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematopoietic and lymphatic system neoplasm treatment provided free

Apply for This Chicago Location

Check if you qualify for this hematopoietic and lymphatic system neoplasm clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Hematopoietic and Lymphatic System Neoplasm Study in Chicago

This clinical trial tests how well a web based toolkit works to improve cancer related emotional distress and anxiety in rural older cancer survivors. Rural older adults with cancer-related distress are particularly vulnerable to poorer mental health and cancer-related outcomes including increased difficulties identifying symptoms of anxiety, a reduced likelihood of knowing when to access mental health services, and a higher likelihood of having poorly managed CRD, even after receiving a psychosocial referral. The web based tool kit called CONNECT addresses digital literacy and supports for cancer-related distress management through interactive activities for setting up telehealth visits, accessing educational materials about cancer-related distress, and providing individualized mental health resource recommendations. Using CONNECT may improve cancer related emotional distress and anxiety in rural older cancer survivors.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

AIM 1: Invited by a member of the study team
AIM 1: In the following or related field:
Healthcare professionals (physicians, nurses, pharmacists, etc.)
Patient advocates and representatives
Researchers in healthcare or technology fields
Healthcare administrators and managers
AIM 1: Must be over 18 years old
AIM 1: English-speaking
AIM 1: Willing and able to provide informed consent
AIM 2 (RURAL OLDER CANCER SURVIVORS): A rural resident based on the Health Resources \& Services Administration (HRSA) rural analyzer
AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report of diagnosis with any cancer
AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report posttreatment (i.e., completion of curative intent therapy including surgery, chemotherapy, molecularly targeted, and endocrine therapy)
AIM 2 (RURAL OLDER CANCER SURVIVORS): Have access to a computer, a smartphone, or a tablet computer
AIM 2 (RURAL OLDER CANCER SURVIVORS): Aged \> 65 years old
AIM 2 (RURAL OLDER CANCER SURVIVORS): Assessed as having Cancer and Treatment Distress scale (CTXD) scores \> 0.85 at screening
AIM 2 (RURAL OLDER CANCER SURVIVORS): Have a caregiver willing to participate
AIM 2 (RURAL OLDER CANCER SURVIVORS): Non-institutionalized
AIM 2 (RURAL OLDER CANCER SURVIVORS): English proficient
AIM 2 (RURAL OLDER CANCER SURVIVORS): Willing and able to provide informed consent
AIM 2 (CAREGIVER): An identified informal caregiver of an eligible ROCS (caregivers include, but are not limited to, a child, partner, or friend; caregivers can reside in a rural or urban area and may or may not live with the ROCS
AIM 2 (CAREGIVER): Have internet access
AIM 2 (CAREGIVER): ≥ 18 years old
AIM 2 (CAREGIVER): Non-institutionalized
AIM 2 (CAREGIVER): English proficient
AIM 2 (CAREGIVER): Willing and able to provide informed consent
AIM 3 (FINAL WORKSHOP): Includes providers, medical and practice managers, patient care coordinators, and medical health technologists

Exclusion Criteria

AIM 2 (RURAL OLDER CANCER SURVIVORS): Experience a cancer recurrence or a new cancer diagnosis during their participation in the trial because of the body of literature that reports increased distress associated with cancer recurrence
AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Are inpatients
AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Cognitive impairment precludes the ability to provide written consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07290543) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematopoietic and Lymphatic System Neoplasm Treatment Options in Chicago, IL

If you're searching for hematopoietic and lymphatic system neoplasm treatment options in Chicago, IL, this clinical trial (NCT07290543) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematopoietic and lymphatic system neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematopoietic and lymphatic system neoplasm clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Chicago, IL

See all essential tremor clinical trials recruiting in Chicago — not just this study.

Browse Essential Tremor Trials in Chicago

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL